The precise relationship between the detection of mixed hematopoietic chimerism (MC) and residual leukaemia (MRD) in longterm disease-free survivors post-BMT needs to be defined, particularly in light of the late relapses that can occur following allogeneic stem cell transplantation (SCT) for CML. We have investigated chimerism and MRD status in 27 patients who were in clinical and haematological remission greater than 5 years post SCT for CML-CP (median 11 yrs, range 5-17). Myeloid and T cell chimerism was assessed using immunomagnetic bead selection and short tandem repeat PCR (STR-PCR) while BCR-ABL mRNA detection using reverse transcriptase PCR (RT-PCR) was performed to detect the presence of MRD. There were 19 recipients of non T depleted marrow (non-TCD), 18 from an HLA identical sibling, 1 from a volunteer unrelated donor (VUD) and 8 recipients of T depleted marrow (TCD), all from an HLA identical sibling. MC was not a common finding in recipients of an unmanipulated graft (2/19, [10.5%]) when compared to TCD BMT (5/8, [62.5%]). Sixteen patients were donor chimeras and MRD negative; 4 donor chimeras showed evidence of intermittently positive bcr-abl expression (transient MRD); 5 patients showed evidence of lineage specific MC in the absence of bcr-abl expression while 2 patients were mixed chimeras and bcr-abl positive. MC was identified in both lymphoid and myeloid fractions by lineage specific STR-PCR. It is notable that 14/15 patients who developed GVHD are full donor chimeras. Similarly, the only 3 recipients of a TCD graft who were found to be full donor chimeras had developed acute GVHD post BMT. One recipient of a non-TCD graft has evidence of both MC and MRD post BMT but did not receive total body irradiation (TBI) as part of the conditioning. In 6 patients (2 TCD and 4 non-TCD) transient MRD was detected but did not lead to hematological relapse. Thus true long term stable mixed chimerism (SMC) can be observed following SCT for CML in the absence of MRD using lineage specific STR-PCR; MC is a rare event following unmanipulated BMT but in long term survivors is associated with disease free survival suggesting that a state of persistent tolerance has been established to surviving normal host immunocompetent cells. Graft versus host disease was extremely rare in patients with MC indicating that tailoring of current protocols including non myeloablative BMT to maximise stable long term MC in the absence of persistent MRD may significantly reduce the incidence of GVHD post stem cell transplant. Precise and sensitive monitoring of chimerism and bcr-abl expression status is relevant in the long term management of CML patients post SCT Detection of minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) is important to schedule early intervention, e.g. DLI. PCR based procedures, detecting tumor specific genetic aberrations, e.g. chromosomal translocations or other molecular markers like T-cell receptor or the immunoglobulin receptor rearrangements have been successfully used for this purpose. However many patients with AML or MDS lack appropriate markers. We asked whether analysis of donor chimerism in early hematopoietic stem cells, i.e. CD34+ cells, might be a sensitive method to monitor minimal residual disease. Material and Methods: 54 patients (28 CML, 14 AML, 7 ALL, 3 MDS, 1 CMMOL, 1 NHL) undergoing BM (n=22) or PBSC (n=32; Tcell depleted: n=11) transplantation from related (n=15) or unrelated (n = 39) donors were prospectively investigated. Seven-teen patients were transplanted after dose reduced conditioning. CD34+ cells were prepared from peripheral blood samples and were sorted (FACS Vantage) after immunomagnetic preenrichment. These data were accomplished with other cellular subsets (T-, NK-, CD15+ and CD14+). Quantification of donor chimerism was done using multiplex STR-PCR with fluorescence detection. Subset chimerism data were compared to overall chimerism and results of nested RT-PCR for the bcr-abl rearrangement. Results: In the 54 patients a median of 8 analyses (range 4-22) covering a median period of 204 days (range 28-832 days) were performed. Four patients experienced secondary graft failure after unrelated transplantation, which was associated with low donor NK-cell chimerism. A hematological relapse was observed in 12/50 engrafting patients (24%) after a median time of 188 days. In nine of these patients, donor chimerism in CD34+ cells decreased 4-80 days (median 28 days) before the clinical diagnosis. In one patient with CML in blast crisis, CD34+ chimerism analysis failed to demonstrate the relapse. In two other patients the relapse developed more than 100 days after the last analysis of chimerism in CD34+ cells. One patient with CML had a molecular relapse at day 211, which was associated with decreasing donor CD34+ chimerism. Reduction of S28
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Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation
One of the major complications after allogeneic stem cell transplantation (SCT) in patients with malignant disease is a high frequency of relapse. We have prospectively analyzed the clinical impact of recipient-derived chimeric cells in 30 patients with acute myeloid leukemia and myelodysplastic syndrome after SCT. In order to improve sensitivity and specificity, all samples were cell-separated by using immunomagnetic beads according to the patient's leukemia phenotype, expressed at diagnosis or relapse before SCT. Twelve out of 30 patients experienced a clinical relapse after SCT. Median follow-up time for patients alive and without relapse (n=15) was 30 (16-47) months. Mixed chimerism in peripheral blood (PB) and bone marrow (BM) Ͼ= 1 month post SCT, in the leukemia-affected cell lineage, was detected in 14/30 patients. Ten of these 14 patients relapsed as compared to 2/16 with donor chimerism (DC) (pϽ0.01). Among the two patients with DC prior to relapse, one patient suffered an extramedullary relapse and in the other patient, with an isolated BM relapse, no BM sample was available prior to relapse. Four patients who still are in CR, showed only MC in BM . In 3 of these patients, MC was only detected at 3 months post SCT, whereas the remaining patient has continued to show MC in the BM. If MC in PB was combined with Ͼ= 2 MC positive BM samples, 10/11 MC patients relapsed versus 2/19 DC patients (pϽ0.001). MC was detected median 66 (23-332) days before hematological relapse. No correlation was found between T-cell MC and relapse. In this study, chimerism analysis showed a higher sensitivity and specificity versus morphological examination. In conclusion, this study provides a rational basis for treatment with adoptive immunotherapy at an earlier time after SCT than today in patients with AML and MDS, in order to treat recurrences of malignant disease. Presence of minimal residual disease (MRD) is an important factor in leukemia therapy. Besides chromosomal alterations as MRD markers RNA expression levels of the Wilms tumor gene (WT1) may serve as a potent diagnostic tool to monitor acute and chronic leukemias. However, methodological difficulties have lead to conflicting results and WT1 analyses are far from beeing routinely performed. Moreover, it is unclear whether WT1 RNA is constantly detectable in all types of leukemia and whether quantitative expression levels differ between different leukemic subtypes. Thus, kinetic studies are lacking which demonstrate a clear WT1 RNA expression pattern in. Based on a recently desribed real-time PCR detection technology we developed a new absolute-quantitative procedure which is easy and quick to perform and allows the routine measurement of WT1 transcripts in clinical samples. Using this approach we investigated WT1 RNA levels in peripheral blood cells of healthy blood donors and of patients with acute myeloid (AML), acute lymphoid (ALL) and chronic myeloid (CML) leukemias. While healthy donors did not exhibit measurable amounts of WT1 transcripts our results demonstrate that WT1 RNA can be detected in all leukemias. Further, we could show that WT1 RNA levels are exclusively dependent from disease progression, therapy and relapse. There was no association between transcript number and FAB subtype or secondary diseases. Instead, we could observe that the amount of detectable WT1 RNA increases gradually with progressive or relapsing leukemia and decreases quickly upon sufficient treatment Moreover, raising WT1 transcript levels were indicative for relapsing leukemia before clinical symptoms became apparent. In CML there was a linear correlation between quantitative values of WT1 RNA and bcr/abl fusion transcripts. We conclude that this procedure is an appropriate tool for the routine molecular monitoring of AML, ALL and CML patients and, that WT1 RNA appears to be a quickly acting indicator for progressive or remissive leukemia.
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Detection of impending graft rejection and leukemia relapse by monitoring of chimerism within specific leukocyte subsets in children after allogeneic stem cell transplantation T. Lion, H. Daxberger, E. Schraml, G. Fritsch, D. Printz, C. Peters, S. Matthes-Martin, A. Lawitschka, H. Gadner (Vienna, AT) PCR-based analysis of chimerism within specific cell fractions isolated by flow-sorting permits detection of patient-derived cells within a 10e3-10e4-fold excess of donor cells. We have used this approach to investigate the possibility of determining the risk of graft rejection and relapse after allogeneic SCT. In a single-center study, we have monitored the kinetics of chimerism in a series of 65 consecutive allogeneic SCTs in children with ALL (n=34), AML (n=17), CML (n=7), or CMML (n=7). For surveillance of minimal residual disease, the immunophenotype of the original leukemic clone has been used to separate specific cell subsets expected to harbor tumor cells, if present. Moreover, T-cell subsets were isolated and analyzed for detection of immunologic processes indicative of graft rejection which may be a condition facilitating subsequent relapse. Within an observation period of over four years, graft rejection and/or relapse were observed in 14 instances. In patients who rejected the graft, persistence of pure recipient-specific patterns or increasing recipient allelic signals had been observed in the T-cell compartment (CD3+) including the helper (CD4+) and suppressor (CD8+) subsets. Kinetics of chimerism indicative of graft rejection had also been seen in five patients who experienced hematologic relapse. The most common observation prior to detection of leukemia relapse was persistence or reappearance and increase of recipient allelic patterns within cell subsets indicative of leukemic cells.
Surveillance of chimerism within specific cell populations revealed imminent rejection or relapse up to 3-6 months before the diagnosis became apparent by morphological investigation of the bone marrow. The data available indicate that monitoring of lineage-specific chimerism in patients after allogeneic stem cell transplantation may provide a basis for timely initiation of appropriate treatment. Autologous stem cell transplantation (SCT) may have curative potential in patients with chronic lymphocytic leukemia (CLL). In a prospective single center study, 77 patients with poor-risk CLL underwent a sequential treatment strategy comprising initial cytoreduction with CHOP or fludarabine, intensive chemotherapy for mobilization of peripheral blood stem cells, and high-dose radiochemotherapy followed by autotransplantation of immuno-magnetically purged grafts. Here we report the results of post transplant quantitative molecular monitoring of the first 20 patients from this series who had an informative IgH CDR3 sequence available. A new Real Time PCR assay (Brueggemann et. al., Leukemia 14:1419 (2000 ) using a clone-specific CDR3 forward primer with JH consensus backward primers and JH consensus Taqman probes was employed to assess MRD levels in peripheral blood samples after SCT. The sensitivity of this assay is 1 clonal B cell in 10E4 to 10E5 polyclonal cells. Results: 3 patients (15%) showed a rapid decline of MRD below the level of sensitivity and stayed negative throughout their follow-up (9-63 months). Similarly, in 14 additional patients (70%) a prompt 2.5-5 log reduction of MRD levels was observed. In 9 of these, low MRD levels were sustained during follow-up (12-24 months) although PCR negativity was never reached, whereas in the other patients MRD levels increased again during the first 24 months and reached the initial values in 3/5 cases (2 of them with clinical relapse). The remaining 3 patients (15%) had less than 2 log MRD level reduction post transplant (2 clinical relapses). Conclusions: Although complete negativity of PCR-detectable MRD is reached only rarely, SCT results in a significant (3-5 log) reduction of MRD levels in the majority of patients. MRD levels may stay low over years. However, patients with increasing levels or those without initial decline of MRD have a high probability of short-term clinical relapse, emphasizing the prognostic value of quantitative CDR3 PCR in CLL. Supported by Deutsche Jose Carreras Leukä mie-Stiftung (DJCLS-R16)
